Enliven Therapeutics, Inc.

ELVN

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001672619

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $476.2M
Warnings	thin data not computable: degenerate inputs, fortress balance sheet
Inputs computable	6 of 14
Graded from	filings received through Mar 3, 2026 242 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$44.26 2026-10-30; market equity $3.2B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 3, 2026

We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. We aim to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Our discovery process combines deep insights into clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 46.8						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(8.3%)	(6.6%)	46.8	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 3.2					
Twelve-month failure probability	0.02%	0.07%	7.3	246	2026-06-30
Altman Z double-prime	31.38	(0.35)	0.8	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	28.66x	2.92x	1.6	829	2025-12-31
Growth and financing, sleeve percentile 32.7					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	78.8%	2.2%	3.5	696	2025-12-31
Net share issuance, one year	22.0%	2.5%	61.9	631	2026-02-19

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	182.8%	7.3%	96
Distance from 52-week high	(27.6%)	(28.7%)	53
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(2.2%)	(1.0%)	47
Book value to price	0.28	0.28	50
Sales to price	not computable	0.30	
Composite equity issuance, five years	281.4%	20.5%	95
Relative strength against the sector, log excess return	0.83	(0.14)	96

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$135.5M
Operating cash flow, four quarters	-$66.9M
Months of runway	24.3
Days since last periodic filing	87 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$55.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$103.7M	2025-12-31	2026-03-03	10-K	26-088232
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$70.3M	2025-12-31	2026-03-03	10-K	26-088232
3	assets	us-gaap:Assets	$476.2M	2025-12-31	2026-03-03	10-K	26-088232
4	assets	us-gaap:Assets	$325.8M	2024-12-31	2026-03-03	10-K	26-088232
5	current assets	us-gaap:AssetsCurrent	$474.9M	2025-12-31	2026-03-03	10-K	26-088232
6	current liabilities	us-gaap:LiabilitiesCurrent	$16.6M	2025-12-31	2026-03-03	10-K	26-088232
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$347.2M	2025-12-31	2026-03-03	10-K	26-088232
8	operating income	us-gaap:OperatingIncomeLoss	-$119.7M	2025-12-31	2026-03-03	10-K	26-088232
9	book equity	us-gaap:StockholdersEquity	$459.6M	2025-12-31	2026-03-03	10-K	26-088232
10	liabilities	us-gaap:Liabilities	$16.6M	2025-12-31	2026-03-03	10-K	26-088232
11	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$158,000	2025-12-31	2026-03-03	10-K	26-088232
12	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$73.2M	2024-12-31	2026-03-03	10-K	26-088232
13	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$44,000	2024-12-31	2026-03-03	10-K	26-088232
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$61.3M	2023-12-31	2025-03-13	10-K	25-038758
15	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$149,000	2023-12-31	2025-03-13	10-K	25-038758
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$32.1M	2022-12-31	2024-03-14	10-K	24-031495
17	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$612,000	2022-12-31	2024-03-14	10-K	24-031495
18	depreciation amortization	us-gaap:Depreciation	$215,000	2022-12-31	2024-03-14	10-K	24-031495
19	operating income	us-gaap:OperatingIncomeLoss	-$38.8M	2022-12-31	2024-03-14	10-K	24-031495
20	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.6M	2022-12-31	2023-02-10	10-K	23-001729
21	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2022-12-31	2024-03-14	10-K	24-031495
22	current assets	us-gaap:AssetsCurrent	$77.8M	2022-12-31	2024-03-14	10-K	24-031495
23	current liabilities	us-gaap:LiabilitiesCurrent	$9.7M	2022-12-31	2024-03-14	10-K	24-031495
24	current assets	us-gaap:AssetsCurrent	$92.7M	2021-12-31	2023-02-10	10-K	23-001729
25	current liabilities	us-gaap:LiabilitiesCurrent	$7.2M	2021-12-31	2023-02-10	10-K	23-001729
26	assets	us-gaap:Assets	$271.9M	2023-12-31	2025-03-13	10-K	25-038758
27	assets	us-gaap:Assets	$83.3M	2022-12-31	2024-03-14	10-K	24-031495
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	59,800,406	2026-02-19	2026-03-03	10-K	26-088232
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,004,425	2025-02-28	2025-03-13	10-K	25-038758

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.